Guadecitabine has now failed three late-phase trials, leaving Otsuka to weigh up the next steps for a drug it acquired in an $886 million takeover.
Astex Pharmaceuticals has reported that Phase III trials of guadecitabine (sSGI-110) failed to meet the primary endpoint of improving overall survival (OS) in leukaemia patients.
Otsuka has some good news to report on the other drug that it obtained in the $886 million acquisition of Astex Pharmaceuticals. ASTX727 combines the chemotherapy decitabine with cedazuridine, an oral inhibitor of cytidine deaminase. A Phase III study evaluating the combo and intermediate to high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia met its primary endpoint, the company said.
Five years ago Otsuka swept in and scooped up California-based Astex for $886 million, determined to get its hands on their promising leukemia drug SGI-110 as it plugged the operations into its global R&D ops.
Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASTRAL-1 Study of Guadecitabine (SGI-110) in Treatment-Naïve AML Patients Ineligible to Receive Intense Induction Chemotherapy